ClinicalTrials.gg
Status unknownNCT02283879Updated May 24, 2016

Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela

A Phase 1 interventional study of Human umbilical cord mesenchymal stem cells in Cerebral Hemorrhage, sponsored by Shenzhen Hornetcorn Bio-technology Company, LTD. Status unknown at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-05-24.

Sponsored by Shenzhen Hornetcorn Bio-technology Company, LTD · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2015), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Cerebral Hemorrhage with a site in China — 58 open to participants now, 61 under way, 5 of them phase 3. Cerebral Hemorrhage · China.

Planned enrollment
72nd of 77
20 · median 180
Started
2015
with 8 others
Phase 1
7 of 122
2 open now
Registered
12th of 122
by date

Among the 122 studies in Cerebral Hemorrhage with a site in China, this one is the 72nd largest by planned enrollment of the 77 interventional ones that give a count, is one of 9 that started in 2015, is one of 7 in phase 1, and was the 12th registered.

Cerebral Hemorrhage

457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

58 of the 122 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 113 Cerebral Hemorrhage studies recruiting now, 59 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Cerebral Hemorrhage with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for cerebral hemorrhage sequela.

Read the detailed description

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into neural cells, which have been confirmed in in vivo and in vitro experiments. There have been few clinical reports describing umbilical cord mesenchymal stem cells for treatment of cerebral hemorrhage.

To investigate the effects of hUC-MSC treatment for cerebral hemorrhage sequela, 20 patients with cerebral hemorrhage will be enrolled and receive 4 times of hUC-MSC transplantation.

03

Conditions studied

  • Cerebral Hemorrhage

Browse trials for

Keywords

  • Human Umbilical Cord Mesenchymal Stem Cell
  • Mesenchymal Stem Cell
  • Cerebral hemorrhage
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 40-70 intracerebral hemorrhage patient
  • With stroke history of more than 3 months, less than 60 months
  • National Institutes of Health stroke scale(NIHSS) score of 7 or more points
  • Patient is stable (normal respiration, afebrile, BP less than mean arterial pressure of 125 mm of Hg, fasting blood sugar \<7 mg, and normal urea/electrolytes for at least 48 hours.)

Exclusion criteria

Exclusion Criteria:

  • History of neurological disease, head injury or psychiatric disorder;
  • Pregnant women;
  • Impaired liver function, abnormal blood coagulation, AIDS, , combine other tumor or special condition;
  • Progressive apoplexy;
  • With malignant tumors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    hUC-MSC treatment

    Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.

    Biological: Human umbilical cord mesenchymal stem cells

Interventions

06

What researchers measure

Primary outcomes

  1. Safety evaluation through vital signs, the results of clinical lab tests and adverse events (AEs)

    Time frame: 12 months

Secondary outcomes

  1. Improvement of infarct size measured by brain MRI

    Time frame: before the transplant and 1, 6, 12 months after transplantation

  2. Modified Barthel index

    Time frame: before and 1, 3, 6 and 12 months after transplantation

  3. National Institutes of Health stroke scale(NIHSS) score

    Time frame: before the transplant and after the transplant 1, 2 and 3 months

07

Study locations

1 site
  • The Fifth Affiliated Hospital Immunotherapy center
    Guangzhou, Guangdong 510000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Dec 2016 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2014
First posted
Nov 5, 2014
Start
Mar 2015
Primary completionEst.
Dec 2016
CompletionEst.
Apr 2017
Last update
May 24, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02283879
Lead sponsor
Shenzhen Hornetcorn Bio-technology Company, LTD
Collaborators
Fifth Affiliated Hospital of Guangzhou Medical University
Responsible party
Sponsor
First posted
Nov 5, 2014
Start date
Mar 2015
Primary completion
Dec 2016 (estimated)
Completion
Apr 2017 (estimated)
Last update
May 24, 2016

Study contacts

Ping J Chen, Professor
principal investigator · Fifth Affiliated Hospital of Guangzhou Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion